[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-ejaculation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-ejaculation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,51,82,108,131,155,177,206,227,252,273,308,328,351,376],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100627682","male-pelvic-floor-muscle-rehabilitation-exercises-100627682",false,"NCT07451808","Male Pelvic Floor Muscle Rehabilitation Exercises","Male Pelvic Floor Muscle Rehabilitation (Kegel Exercises) Pelvic Floor Muscle Training","Inclusion Criteria:\n\n* Men 18 - 60 years of age\n* Must be able to achieve an erection\n\nExclusion Criteria:\n\n* Underlying medical conditions or poor health\n* Men who fall within the obese category based on standard body mass index (BMI) measurements",true,"MALE","18 Years","60 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Phase I\n\nG128 Study Objective\n\nThe ischiocavernosus (IC) and bulbospongiosus (BS) muscles are vital components of the superficial perineal layer, serving as the foundation for male sexual health and performance. These muscles play a primary role in achieving and maintaining erections by compressing the veins to trap blood within the erectile tissues. Furthermore, they are responsible for the rhythmic contractions necessary for ejaculation and the physiological sensations associated with orgasm.\n\nBeyond their role in sexual function, these muscles provide critical structural support to the pelvic floor and assist in urinary control. By working in tandem, the IC and BS muscles ensure penile rigidity while stabilizing the surrounding pelvic structures. Maintaining the strength and coordination of these muscles is essential for overall reproductive health and the prevention of pelvic floor dysfunction.\n\nThe primary objective of this clinical trial is to evaluate the clinical efficacy and therapeutic potential of Exercise G128 in strengthening the male pelvic floor musculature. Furthermore, the study aims to establish a comprehensive safety profile for Exercise G128 during active participation. The research seeks to address the following core investigative questions:\n\nTo what extent does Exercise G128 improve the tonicity and contractile strength of the IC and BS muscles?\n\nWhat is the incidence and nature of adverse medical events or physiological stressors reported by participants while performing the Exercise G128 protocol?\n\nResearchers will conduct a comparative analysis, benchmarking the physiological outcomes of Exercise G128 against existing clinical data regarding the efficacy of traditional Kegel exercises.\n\nParticipant Requirements:\n\nAdhere to a structured regimen, performing Exercise G128 four times weekly over a one-month intervention period.\n\nAttend bi-weekly telehealth consultations via video conferencing for supervised clinical assessments, progress monitoring, and physiological testing.\n\nMaintain a detailed daily log documenting functional progress, as well as any instances of physical exertion or soreness that necessitated a temporary cessation of the exercise protocol.",[28,29,30],"Erectile Dysfunction","Urinary Incontinence","Premature Ejaculation",[32,33,34,35,36,37,38],"Dripping or leakage","urinary incontinence","Kegel exercises for men","ischiocavernosus muscle","bulbospongiosus muscle","Erectile dysfunction (ED)","Premature ejaculation","NOT_YET_RECRUITING","2026-06-07",{"date":42,"type":43},"2026-06-10","ACTUAL",{"date":45,"type":22},"2026-12",{"date":47,"type":22},"2027-12",{"name":49,"class":50},"Dream Video LLC","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100638532","pelvic-floor-therapies-for-lifelong-premature-ejaculation-100638532","NCT07627438","Pelvic Floor Therapies for Lifelong Premature Ejaculation","Electromagnetic Pelvic Floor Stimulation Versus Biofeedback-Assisted and Conventional Pelvic Floor Muscle Training in Men With Lifelong Premature Ejaculation: A Randomized Controlled Trial","PE-PFMT","Inclusion Criteria:\n\n* Men aged 18 to 50 years.\n* Diagnosis of lifelong premature ejaculation.\n* Intravaginal ejaculatory latency time less than 1 minute.\n* Ability and willingness to comply with the treatment protocol and follow-up visits.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Erectile dysfunction.\n* Neurological disease.\n* Previous pelvic surgery.","50 Years",{"count":61,"type":22},150,[25],"This randomized controlled trial will compare three pelvic floor-based treatment modalities in men with lifelong premature ejaculation: electromagnetic pelvic floor stimulation, biofeedback-assisted pelvic floor muscle training, and conventional pelvic floor muscle training. A total of 150 men aged 18 to 50 years with lifelong premature ejaculation and stopwatch-measured intravaginal ejaculatory latency time of less than 1 minute will be randomly assigned to one of the three treatment groups. The primary outcome will be the change in intravaginal ejaculatory latency time from baseline to the end of treatment at 6 weeks. Secondary outcomes will include changes in Premature Ejaculation Diagnostic Tool score, International Index of Erectile Function-5 score, patient-reported ejaculatory control, sexual satisfaction, partner satisfaction, treatment adherence, and adverse events.",[30,65,66],"Lifelong Premature Ejaculation","Male Sexual Dysfunction",[68,69,70],"Pelvic floor muscle training","Biofeedback","Electromagnetic pelvic floor stimulation","RECRUITING","2026-05-30",{"date":74,"type":43},"2026-06-04",{"date":76,"type":43},"2026-04-26",{"date":78,"type":22},"2027-04",{"name":80,"class":50},"Tanta University",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":81},"100639219","effect-of-prostatic-urethra-and-seminal-vesicle-morphometry-on-ejaculation-100639219","NCT07614854","Effect of Prostatic Urethra and Seminal Vesicle Morphometry on Ejaculation","The Effect of Prostatic Urethral and Seminal Vesicle Morphometry on Multiparametric Prostate Magnetic Resonance Imaging on Ejaculation","Inclusion Criteria:\n\n* \\- Male aged 18 to 55 years\n* In a stable, heterosexual, monogamous relationship with the same female partner for at least 6 months\n* Normal erectile function defined as IIEF-15 erectile function domain score ≥26\n* Scheduled for clinically indicated multiparametric prostate MRI due to elevated PSA or hematospermia\n* Not using any medication that may affect sexual function or psychological status (e.g., SSRIs, PDE5 inhibitors)\n\nExclusion Criteria:\n\n* Any major psychiatric or somatic disorder\n* Hormonal disorders such as hypothyroidism or hyperthyroidism\n* Erectile dysfunction (IIEF-15 erectile function domain score \\\u003C26)\n* Age below 18 or above 55 years","55 Years",{"count":61,"type":22},"OBSERVATIONAL","The goal of this observational study is to learn whether the size and shape of the prostatic urethra and seminal vesicles - measured on multiparametric prostate MRI (mpMRI) - are related to premature ejaculation (PE) severity in men aged 18-55.\n\nThe main questions it aims to answer are:\n\n* Do men with premature ejaculation have different prostatic urethral length and angulation compared to men without PE?\n* Do men with premature ejaculation have different seminal vesicle dimensions compared to men without PE?\n* Do prostatic urethra and seminal vesicle measurements on mpMRI correlate with PE severity scores (PEDT) and ejaculation latency time (IELT)?\n\nResearchers will compare men with premature ejaculation to healthy men without ejaculatory complaints to see if specific anatomical features are associated with PE severity.\n\nParticipants will:\n\n* Undergo a multiparametric prostate MRI that is already scheduled as part of their routine medical care\n* Complete validated questionnaires about ejaculation and sexual function (PEDT, PEP, IELT, IIEF-15)\n* Provide a blood sample for routine hormone level measurements",[30,94],"Ejaculation",[96,97,98],"Prostatic Urethra","seminal vesicle","morphometry",{"date":100,"type":43},"2026-06-03",{"date":102,"type":22},"2026-05-10",{"date":104,"type":22},"2026-08-10",{"name":106,"class":107},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":16,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":81},"100626958","the-effectiveness-of-exercise-in-the-treatment-of-erectile-dysfunction-and-premature-ejaculation-100626958","NCT07442396","The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation","The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation: a Randomized Controlled Trial.","Inclusion Criteria\n\n* Male individuals aged 25-45 years\n* Individuals diagnosed with erectile dysfunction and premature ejaculation\n* Individuals who voluntarily agree to participate in the study and sign the informed consent form\n* Individuals who have the physical and cognitive capacity to participate in pelvic floor physiotherapy applications\n\nExclusion Criteria\n\n* Individuals with a history of surgery in the pelvic region\n* Individuals with a diagnosis of neurological disease or neurological disorder that may affect pelvic floor muscle function\n* Presence of active infection, inflammation, or painful pathology in the pelvic region\n* Individuals who regularly use medications that significantly affect sexual function\n* Individuals with serious psychiatric illness or cognitive impairment that may hinder study compliance","25 Years","45 Years",{"count":118,"type":22},50,[25],"The aim is to investigate the effectiveness of exercise in the treatment of erectile dysfunction and premature ejaculation.",[28,30],"2026-03-02",{"date":124,"type":43},"2026-03-03",{"date":126,"type":43},"2026-03-01",{"date":128,"type":22},"2026-07-10",{"name":130,"class":50},"Uskudar University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":81},"100626333","phase-2-study-to-evaluate-the-potential-effects-of-kh-001-on-intravaginal-ejaculatory-latency-time-ielt-patient-reported-outcomes-and-safety-in-men-with-lifelong-premature-ejaculation-lpe-100626333","NCT07434271","Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)","Explorative Double-Blind Placebo Controlled Crossover Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)","Inclusion Criteria:\n\n1. Male participants aged 18 to 65 years (inclusive) at the time of informed consent.\n2. In a stable (≥6 months) monogamous heterosexual relationship.\n3. Self-reported lifelong premature ejaculation (LPE), meeting the ISSM definition.\n4. Intravaginal Ejaculatory Latency Time (IELT) ≤1 minute on at least 75% of intercourse attempts during the 4-week run-in period.\n5. PEDT (Premature Ejaculation Diagnostic Tool) score ≥11.\n6. Normal erectile function (IIEF Questions 1-5 sum score ≥21).\n7. Personal distress rated at least \"moderate\" on the Premature Ejaculation Profile (PEP) after the run-in period.\n8. In good general health and medically stable as per investigator's judgment.\n9. Willing to attempt intercourse at least 4 times during each 4-week treatment period.\n10. For partners of childbearing potential: agreement to use acceptable contraception methods from Screening until 30 days post last dose.\n11. Willing to avoid sperm donation from first dose until at least 90 days after the last dose.\n12. Willing to limit alcohol intake on dosing days.\n13. Ability to provide written informed consent and comply with study requirements.\n\nExclusion Criteria:\n\n1. IELT \\>1 minute on more than 25% of attempts during the run-in period.\n2. Fewer than 4 intercourse attempts during the run-in period.\n3. Self-rated control of ejaculation as fair, good, or very good on the PEP.\n4. Low personal distress (\"not at all\" or \"a little bit\") on the PEP.\n5. Erectile dysfunction (IIEF Questions 1-5 sum score \\\u003C21).\n6. Significant anatomical penile deformities or history of penile surgery affecting erection.\n7. History of other forms of sexual dysfunction.\n8. Untreated or unstable thyroid dysfunction.\n9. Recent use (within 4 weeks) of SSRIs, SNRIs, PDE5 inhibitors, MAO inhibitors, alpha blockers, 5-alpha reductase inhibitors, topical anesthetics, or tramadol.\n10. History of sexual dysfunction treatments like Botox for PE in the past 6 months.\n11. Active or uncontrolled sexually transmitted infections.\n12. Severe psychiatric disorders, major depression, or suicidal ideation.\n13. Clinically significant laboratory abnormalities or cardiovascular risk factors.\n14. Positive drug screen (unless explained by prescription use).\n15. Positive for HIV, Hepatitis B, or Hepatitis C.\n16. Planned major surgery during study period.\n17. BMI outside 18.0-35.0 kg\u002Fm² or weight \\\u003C50 kg.","65 Years",{"count":140,"type":22},40,[142],"PHASE2","This is a Phase 2a, double-blind, placebo-controlled, crossover study evaluating the efficacy, safety, and patient-reported outcomes of KH-001 in men with lifelong premature ejaculation (LPE). Approximately 40 participants will receive KH-001 or placebo in two 4-week treatment periods separated by a washout.",[30],"2026-02-20",{"date":147,"type":43},"2026-02-25",{"date":149,"type":43},"2025-12-01",{"date":151,"type":22},"2026-08-30",{"name":153,"class":154},"Kadence Bio","INDUSTRY",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":81},"100548762","effectiveness-of-pelvic-floor-therapy-for-the-management-of-erectile-dysfunction-and-premature-ejaculation-100548762","NCT06425211","Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.","Inclusion Criteria:\n\nOverall:\n\n* Men over 18 years of age\n* Erectile dysfunction or premature ejaculation for at least 6 months\n* Sexual activity with a heterosexual partner at least once a week\n* Signing of informed consent before the start of the study\n\nFor the premature ejaculation group:\n\n* Premature ejaculation according to the International Society of Sexual Medicine (ISSM) criteria\n* Premature Ejaculation Diagnosis Tool (PEDT) questionnaire score greater than 11\n\nFor the erectile dysfunction group:\n\n* Clinical diagnosis of primary erectile dysfunction\n* International Index Erectile Function - Erectile Function domain (IIEF-EF) score less than 26\n\nExclusion Criteria:\n\n* Pharmacological treatment for erectile dysfunction or premature ejaculation in the last 3 months\n* Erection Hardness Score (EHS) greater than 3 for patients with erectile dysfunction\n* History of hypogonadism or suspected hypogonadism due to Aging Males Symptoms (AMS) score greater than 36 for patients with erectile dysfunction\n* History of pelvic radiotherapy\n* Pacemaker or cardiac arrhythmia, epilepsy\n* History of spinal cord trauma or spinal surgeries.\n* Inability to attend therapies or controls\n* Illiteracy or cognitive disability that prevents you from completing the questionnaires\n* Psychiatric, psychological disorders, or cognitive deficiencies\n* Injuries in the area of application of the therapy\n* Active pelvic organ cancer","100 Years",{"count":163,"type":22},66,[25],"The objective of this clinical trial is to evaluate the effectiveness of pelvic floor therapy for the management of erectile dysfunction and premature ejaculation in patients with erectile dysfunction and premature ejaculation. The main question to answer is:\n\nWhat is the effectiveness of pelvic floor therapy (electrostimulation, biofeedback, and therapeutic exercise) for the treatment of patients with erectile dysfunction and or premature ejaculation?\n\nPatients will:\n\n* Have an initial consultation of pelvic floor rehabilitation before therapy.\n* Be given pelvic floor therapy.\n* Have a secondary consultation of pelvic floor rehabilitation after therapy.\n\nThree intervention groups will be included: Group 1: Patients with premature ejaculation Group 2: Patients with erectile dysfunction Group 3: Patients with erectile dysfunction and premature ejaculation.",[28,167,30,168],"Premature (Early) Ejaculation","Pelvic Floor; Weak","2026-01-22",{"date":171,"type":43},"2026-01-23",{"date":173,"type":43},"2021-10-30",{"date":45,"type":22},{"name":176,"class":154},"Boston Medical Group",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":116,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100611134","hyaluronic-acid-vs-botulinum-toxin-injection-in-treatment-of-lifelong-drug-resistant-premature-ejaculation-randomized-study-100611134","NCT07236632","Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study","Hyaluronic Acid Versus Botox Injection in Treatment of Life Long Drug Resistant Premature Ejaculation. Which is Better? Randomized Study","Inclusion Criteria:\n\n* Adult male patients aged 22 to 45 years.\n* Sexually active and in a stable heterosexual relationship.\n* Circumcised.\n* Able to understand and comply with study procedures and follow-up visits.\n* Diagnosed with lifelong drug-resistant premature ejaculation, defined as persistent ejaculation within one minute of penetration despite prior pharmacologic or behavioral therapy.\n* Normal serum total testosterone, prolactin, and thyroid-stimulating hormone levels.\n* Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence or history of erectile dysfunction or other sexual or ejaculatory disorders such as retrograde ejaculation or acquired premature ejaculation.\n* History of acute or chronic prostatitis.\n* Any debilitating medical condition including hepatic failure, renal failure, or uncontrolled diabetes mellitus.\n* Previous pelvic or spinal surgery.\n* Prior chemotherapy or radiotherapy.\n* Use of antipsychotic or neuroactive medications that may affect ejaculation.\n* History of substance abuse or current drug dependence.\n* Presence of penile prosthesis, penile deformity, or anatomic abnormalities of the glans or shaft.\n* Known hypersensitivity or allergy to botulinum toxin or hyaluronic acid preparations.\n* Any condition that, in the investigator's opinion, may interfere with the safety or evaluation of the study treatment.","22 Years",{"count":186,"type":22},80,[25],"Premature ejaculation (PE) is one of the most common male sexual dysfunctions, often resistant to conventional pharmacological and behavioral treatments. This randomized clinical trial aims to compare the safety and efficacy of two minimally invasive treatment options - hyaluronic acid (HA) injection into the glans penis versus botulinum toxin type A injection into the bulbospongiosus muscle - in men with lifelong drug-resistant premature ejaculation. Eighty participants will be randomly assigned in a 1:1 ratio to receive either HA or botulinum toxin injection. The primary outcome is change in intravaginal ejaculatory latency time (IELT). Secondary outcomes include changes in Premature Ejaculation Diagnostic Tool (PEDT), Arabic Index of Premature Ejaculation (AIPE) scores, Premature Ejaculation Profile (PEP), patient satisfaction, and treatment-related adverse events during a 12-month follow-up period.",[30],[191,192,94,193,194,195,196],"Hyaluronic Acid","Botulinum Toxins","Glans Penis","Bulbospongiosus Muscle","Intradermal Injections","Drug Resistance","2025-11-15",{"date":199,"type":43},"2025-11-19",{"date":201,"type":22},"2025-12-15",{"date":203,"type":22},"2026-12-15",{"name":205,"class":50},"Benha University",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":81},"100597324","therapeutic-outcomes-of-selective-serotonin-reuptake-inhibitors-and-phosphodiesterase-5-inhibitors-combination-therapy-versus-monotherapy-100597324","NCT07057011","Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy","Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy in Premature Ejaculation Patients With the Serotonin Transporter Gene Polymorphism (SLC6A4)","Inclusion Criteria:\n\n* Patients with PE: Men aged 18-60 years with a diagnosis of PE according to the International Society for Sexual Medicine (ISSM) criteria.\n* Healthy controls: Men aged 18-60 years without a history of PE or other sexual dysfunctions.\n\nExclusion Criteria:\n\n* Other sexual dysfunctions: Erectile dysfunction, delayed ejaculation, or other sexual disorders.\n* Cardiovascular disease: history of cardiovascular disease, hypertension, or stroke.\n* Neurological or psychiatric disorders: Conditions that may affect sexual function, such as depression, anxiety, or Parkinson's disease.\n* Medications affecting sexual function: Current use of medications that may impact sexual function, such as antidepressants or antipsychotics.",{"count":214,"type":22},60,[25],"Premature ejaculation (PE) is a prevalent male sexual dysfunction that affects as many as 20-30% of men regardless of age and ethnicity.The International Society for Sexual Medicine defines premature ejaculation as a male sexual dysfunction characterised by ejaculation that always or nearly always occurs before or within about 1 minute of vaginal penetration from the first sexual experience (lifelong premature ejaculation) or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less (acquired premature ejaculation), the inability to delay ejaculation on all or nearly all vaginal penetrations and with negative personal consequences include distress, bother, frustration, and avoidance of sexual intimacy.",[30],"2025-07-06",{"date":220,"type":43},"2025-07-09",{"date":222,"type":22},"2025-07-01",{"date":224,"type":22},"2026-02-10",{"name":226,"class":50},"South Valley University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":81},"100598167","comparison-of-the-efficacy-and-safety-of-dapoxetine-kegel-exercises-and-acupuncture-in-the-treatment-of-premature-ejaculation-a-randomized-double-blind-placebo-controlled-trial-100598167","NCT07067970","Comparison of the Efficacy and Safety of Dapoxetine, Kegel Exercises, and Acupuncture in the Treatment of Premature Ejaculation: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Male, aged 18-50 years. Diagnosed with lifelong or acquired PE per ISSM criteria (IELT \\\u003C 2 minutes, lack of ejaculatory control, and associated distress or interpersonal difficulties).\n\nIn a stable sexual relationship with a partner for at least 6 months. Willing to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Presence of erectile dysfunction (diagnosed via International Index of Erectile Function score \\\u003C 21).\n\nSevere psychiatric disorders (e.g., major depression, bipolar disorder) or neurological conditions (e.g., multiple sclerosis, Parkinson's disease).\n\nCurrent use of selective serotonin reuptake inhibitors (SSRIs) or other psychotropic medications.\n\nHistory of alcohol or substance dependence. Known contraindications to dapoxetine (e.g., hepatic impairment) or acupuncture (e.g., bleeding disorders).\n\nPrevious pelvic floor surgery or trauma affecting pelvic floor muscles.",{"count":234,"type":22},250,[25],"This study aims to compare the efficacy and safety of dapoxetine, Kegel exercises, acupuncture, and their placebo controls in the treatment of premature ejaculation (PE). PE is a common male sexual dysfunction characterized by ejaculation occurring within one minute of vaginal penetration, causing distress or interpersonal difficulties (Althof et al., 2014). A total of 250 male participants will be randomized into five groups (dapoxetine, placebo, Kegel exercises, acupuncture, sham acupuncture) for a 12-week treatment period followed by a 4-week follow-up. The primary outcome is the increase in intravaginal ejaculation latency time (IELT), with secondary outcomes including the Premature Ejaculation Diagnostic Tool (PEDT) score, Sexual Quality of Life-Male (SQoL-M) score, and adverse effects.",[30],[239,240,241,242,243],"premature ejaculation","acupuncture","dapoksetin","kegel","sham-acupuncture",{"date":245,"type":43},"2025-07-16",{"date":247,"type":22},"2025-10-01",{"date":249,"type":22},"2026-12-01",{"name":251,"class":50},"Medipol University",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100559899","brain-activity-during-sexual-behavior-in-patients-with-primary-premature-ejaculation-a-clinical-trial-100559899","NCT06570135","Brain Activity During Sexual Behavior in Patients With Primary Premature Ejaculation a Clinical Trial","Inclusion Criteria (primary premature ejaculation subjects):\n\n* patients' age varied from 18 to 45 years；\n* patients met the 2014 International Society for Sexual Medicine (ISSM) definition criteria for PPE；\n* patients had a stable, heterosexual relationship with a single sexually active female partner for at least 6 months and with at least two sexual intercourses a week and kept stable during the study period;\n* Patients with premature ejaculation lasting longer than 6 months；\n* patients were identified if their scores were higher than 9 on the Chinese version of Premature Ejaculation Diagnostic Tool (PEDT);\n* patients had no history of any previous therapies for PE or had recently stopped the therapies for at least 3 months\n* patients had fully informed consent, signed informed consent form\n\nInclusion Criteria (Non-premature ejaculation subjects):\n\n* Men between the ages of 18-45 years were included according to an age difference of \\\u003C3 years between each patient and the primary premature ejaculation group, and if more than one volunteer was eligible at the same time, the one with the closest age was selected；\n* Patient does not meet the 2014 International Society for Sexual Medicine (ISSM) criteria for defining premature ejaculation；\n* patients had a stable, heterosexual relationship with a single sexually active female partner for at least 6 months and with at least two sexual intercourses a week and kept stable during the study period;\n* patients had fully informed consent, signed informed consent form；\n\nExclusion Criteria:\n\n* patients were diagnosed with secondary PE, variable PE, and subjective PE;\n* patients were using medications for endocrinological, metabolic, chronic systemic, or psychiatric diseases;\n* patients were abusing alcohol or illegal drugs；\n* patients were diagnosed with erectile dysfunction (ED) if their scores were \\\u003C21 on the abridged five-item International Index of Erectile Function (IIEF-5)\n* patients were diagnosed with sexual hormone abnormalities, hyperthyroidism, hypothyroidism, Peyronie's disease, prostatitis, urethritis, or urinary tract infection;\n* patients with head injuries that prevent them from completing near-infrared light brain function imaging\n* Patients with severe schizophrenia, anxiety, depression or other neurological symptoms or poor compliance",{"count":259,"type":22},20,[25],"This is a controlled study of patients with and without primary premature ejaculation. It is based on near-infrared spectroscopy (NIRS) functional brain imaging to detect and compare changes in brain activity in resting and task states (Simulated Sex) between the two groups of patients.",[30],"2025-04-14",{"date":265,"type":43},"2025-04-17",{"date":267,"type":43},"2025-04-08",{"date":269,"type":22},"2025-12-30",{"name":271,"class":50},"Xijing Hospital",2,{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":16,"sex":280,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":91,"phases":4,"briefSummary":284,"conditions":285,"keywords":292,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":81},"100562615","ejaculatory-and-orgasmic-dysfunction-registry-100562615","NCT06605469","Ejaculatory and Orgasmic Dysfunction Registry","Ejaculatory and Orgasmic Dysfunction Registry (Climax Registry)","Inclusion Criteria:\n\n* Men being treated for either ejaculatory and\u002For orgasmic dysfunction\n* For partners, inclusion is being a sexual partner of a man with ejaculatory and\u002For orgasmic dysfunction who is receiving treatment\n\nExclusion Criteria:\n\n* None","ALL",{"count":282,"type":22},500,"3 Years","The goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and\u002For orgasmic dysfunctions in men. The objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and\u002For orgasmic dysfunction.\n\nParticipants will submit questionnaires about their diagnosis and treatment efficacy and multiple time intervals.",[286,30,287,288,289,290,291],"Ejaculatory Dysfunction","Delayed Ejaculation","Anorgasmia","Anejaculation","Dysejaculation","Dysorgasmia",[293,239,294,295,296,297,298],"ejaculatory dysfunction","delayed ejaculation","anorgasmia","anejaculation","dysejaculation","dysorgasmia","2025-02-12",{"date":301,"type":43},"2025-02-14",{"date":303,"type":43},"2024-05-30",{"date":305,"type":22},"2029-05-31",{"name":307,"class":50},"Charitable Union for the Research and Education of Peyronie's Disease",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":316,"studyType":91,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":272},"100568176","development-and-validation-of-an-anxiety-disorder-prediction-model-for-premature-ejaculation-patients-100568176","NCT06677814","Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients","Inclusion Criteria:\n\n* Comply with the international medical premature ejaculation diagnostic criteria\n* Individuals with a \"heterosexual\" orientation who engage in vaginal intercourse\n* Having a stable relationship with \"monogamy\"\n* The International Index of Erectile Function-5 scale is ≥17 points, indicating that the patient has no erectile dysfunction or only mild erectile dysfunction\n* Be informed of the purpose of this study, support this study, and complete the informed consent form\n\nExclusion Criteria:\n\n* Minors under the age of 18\n* Individuals with a sexual orientation of \"gay\" or \"bisexual\"\n* The judgment of \"ejaculation too fast\" is based only on masturbation or non-vaginal sexual intercourse\n* The score of the premature ejaculation self-assessment scale is ≤8 points\n* Suffering from diseases that may affect anxiety symptoms (hyperthyroidism\u002Fhypothyroidism, digestive diseases, malignant tumors, etc.)\n* Within 2 months, have taken anti-anxiety drugs and\u002For drugs for PE treatment\n* Those with a history of severe neurological diseases (such as epilepsy) and\u002For a history of schizophrenia, bipolar disorder, or other mental disorders\n* Poor cooperation during diagnostic interviews",{"count":315,"type":22},700,"3 Months","Background:\n\nPremature ejaculation (PE) is a common sexual dysfunction that can significantly impact the quality of life and psychological well-being of affected individuals. Anxiety disorders, often comorbid with PE, exacerbate symptoms and complicate treatment outcomes. There is a critical need for a reliable prediction model to identify patients at risk of developing anxiety disorders associated with PE.\n\nObjective:\n\nThe primary aim of this study is to develop and validate a predictive model that accurately identifies premature ejaculation patients who are at high risk of developing anxiety disorders. The model will be designed to facilitate early intervention strategies and improve patient outcomes.\n\nMethods:\n\nThis prospective observational study will enroll male patients diagnosed with PE from multiple clinical centers. Participants will undergo comprehensive assessments including validated questionnaires, clinical interviews, and medical history reviews to collect baseline data on potential predictors of anxiety disorders. Machine learning algorithms will be utilized to analyze the collected data and derive a predictive model. External validation will be conducted using a separate cohort of patients not involved in the initial model development phase.\n\nOutcome Measures:\n\nThe primary outcome measure will be the accuracy of the predictive model in identifying patients who subsequently develop anxiety disorders within a predefined follow-up period. Secondary outcomes include evaluating the model's sensitivity, specificity, positive predictive value, and negative predictive value.\n\nSignificance:\n\nSuccessful development and validation of this prediction model could lead to improved patient care through targeted interventions and personalized treatment plans for those at risk of anxiety disorders related to PE. This research may also contribute to a better understanding of the complex interplay between sexual dysfunction and mental health.",[30,319],"Anxiety","2024-11-05",{"date":322,"type":43},"2024-11-07",{"date":324,"type":43},"2024-03-25",{"date":326,"type":22},"2026-05-01",{"name":271,"class":50},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":16,"sex":17,"minAge":335,"maxAge":59,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100559990","clinical-study-to-reduce-premature-ejaculation-in-healthy-adult-men-100559990","NCT06571318","Clinical Study to Reduce Premature Ejaculation in Healthy Adult Men","A Randomized, Double Blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Perform Capsule in the Management of Stress-induced Premature Ejaculation in Healthy Adult Men","Inclusion Criteria:\n\n1. Male participants aged 21-50 years both inclusive suffering from a. PE or b. ED\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participant having baseline IELT of less than 2 min\n4. Participants meeting with diagnostic criteria for PEP score greater than or equal to 11\n5. Participants who have scored 11 to 25 on the Erectile Function EF domain of the International Index of Erectile Function IIEF at screening visit a subset of 15 patients only that is 5 participants from each group\n6. Participants should be in an active stable sexual relationship only married participants for the entire duration of the study\n7. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Previous events or other severe conditions that may affect premature ejaculation\u002Ferectile dysfunction, including but not limited to spinal trauma or pelvic surgery\n2. Participants with genital anatomical deformities, including but not limited to penile deformities\n3. Participants for whom sexual activity is inadvisable because of their underlying disease status\n4. Female partners experiencing sexual dysfunction, such as painful intercourse, low libido, or other forms of sexual dysfunction, as well as pregnant individuals\n5. Presence or history of any of the following disorders\u002Fdisease within the past 3 months, that might have impact on the clinical trial as per the investigator discretion. cardiovascular, b) cerebrovascular, c) dermatological, d) gastrointestinal, e) gynaecological, f) hematological, g) hepatic, h) malignancy, i) metabolic, j) musculoskeletal, k) neurological, l) psychiatric, m) thyroid n) psychological, o) renal, p) respiratory, q) venereal, r) any other major disorders\n6. Participants that have undergone radical prostatectomy, spinal cord injury, or any other surgery of urogenital organs;\n7. Participants with history or presence of significant alcoholism or drug abuse within the past 1 year\n8. Participants with history or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco\u002Fnicotine products more than 10 times per day\n9. Any concomitant treatment that is not permissible including but not limited to (nitrates, anti-androgens, chemotherapy agents, radiotherapy, etc).\n10. Recent participation in another clinical trial or receiving some other drug during the study besides that in the protocol\n11. Known hypersensitivity to any of the ingredients of investigational product\n12. Participants concurrent use of sildenafil or other such drugs in the PDE5 inhibitor family, energy supplements, herbal or pharmaceutical aphrodisiacs, body composition enhancing agents, or other concurrent medication such as beta blockers, contraceptives, and psychotropic medications, nutraceutical, or ayurvedic supplement for stress and\u002For PE management\n13. Other conditions, which in the opinion of the investigators, makes the participant unsuitable for enrolment or could interfere with his\u002Fher participation in, and completion of the protocol.","21 Years",{"count":214,"type":22},[25],"The current study focuses on clinical validation of efficacy of nutraceutical product in management of male health. In healthy adult men with induced premature ejaculation, the introduction of these nutraceuticals has been associated with notable improvements in quality of life. These supplements help them for enhanced sexual satisfaction, increased control over ejaculation, and a reduction in performance anxiety. The psychological benefits are significant, as the improvement in sexual function can lead to higher self-confidence and a more positive outlook on life.",[30,340],"Stress",[30,340],"2024-08-23",{"date":344,"type":43},"2024-08-26",{"date":346,"type":22},"2024-09-05",{"date":348,"type":22},"2024-12-28",{"name":350,"class":154},"Herbolab India Pvt. Ltd.",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":81},"100548763","phase-3-effectiveness-and-safety-of-tens-therapy-for-premature-ejaculation-100548763","NCT06425224","Effectiveness and Safety of TENS Therapy for Premature Ejaculation","Effectiveness and Safety of Transcutaneous Posterior Tibial Nerve Stimulation Therapy for the Management of Patients With Premature Ejaculation. Phase III Clinical Trial","TENSPE2","Inclusion Criteria:\n\n* Primary premature ejaculation according to the definition of the International Society for Sexual Medicine (ISSM-International Society for Sexual Medicine) (30): a) ejaculation always or almost always occurs within the first minute after penetration, b) inability to delay ejaculation in all or almost all penetrations, c) negative personal consequences are generated, such as stress, annoyance, frustration and\u002For avoidance of sexual intimacy.\n* Age between 18 and 62 years.\n* PEDT score greater than 11.\n* Stable heterosexual relationship for at least 6 months with interest in maintaining it for at least the duration of the study.\n* Sexual activity at least once a week.\n* Minimum chronicity of PD of 6 months.\n* Voluntary participation in the study.\n* Signing of the informed consent prior to participation in the study.\n\nExclusion Criteria:\n\n* IIEF-EF score less than 26.\n* Glaucoma\n* Clinically significant comorbidity: cardiovascular, hepatic, thromboembolic, neurological, locomotor, endocrine, oncological, renal or rheumatological.\n* History of retroperitoneal surgery, radiotherapy or multiple sclerosis.\n* History of mental illness: depression, anxiety, suicidal behavior, bipolar disorder, agoraphobia, dysthymia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, psychiatric disorder, reported by the patient or due to the use of a medication for one of these conditions.\n* Consumption of medications that affect ejaculatory control such as psychiatric medications, opioid analgesics, alpha blockers.\n* Treatment for PE in the last 3 months.\n* Treatment for epileptic syndromes or Parkinson's disease.\n* Use of pacemaker or cardiac defibrillator.\n* Skin lesions in the area where the electrodes are placed.\n* Abuse or dependence on psychoactive substances: alcohol, hallucinogenic drugs.\n* Couple who are pregnant or interested in conceiving a pregnancy in the next 3 months.","62 Years",{"count":361,"type":22},129,[363],"PHASE3","The objective of this clinical trial is to evaluate the effectiveness and safety of transcutaneous posterior tibial nerve stimulation therapy in patients with premature ejaculation. The main question to answer is:\n\nCan the effectiveness and safety of transcutaneous electrostimulation of the posterior tibial nerve alone and combined with standard pharmacological treatment be evaluated in men with lifelong premature ejaculation, compared to standard pharmacological treatment with dapoxetine?\n\nPatients will:\n\nBe randomized in acontrolled clinical trial. Patients with a diagnosis of premature ejaculation who attend Boston Medical Group clinics in Mexico City will be included.\n\nBe assigned by randomization to one of three treatment groups:\n\n* Group 1: Tens therapy + dapoxetine placebo on demand.\n* Group 2: Standard treatment (dapoxetine 30 mg as needed) + placebo therapy.\n* Group 3: Tens therapy + standard treatment (dapoxetine 30 mg as needed).",[30,366,367],"Sex Disorder","TEN","2024-05-17",{"date":370,"type":43},"2024-05-22",{"date":372,"type":43},"2022-06-15",{"date":374,"type":22},"2025-06",{"name":176,"class":154},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":4},"100443321","phase-3-efficacy-and-safety-of-toronto-association-in-the-treatment-of-erectile-dysfunction-and-premature-ejaculation-100443321","NCT05052879","Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation","National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation","Inclusion Criteria:\n\n* Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;\n* Male participants, with age greater than or equal to 18 years;\n* Heterosexual, sexually active participants in a stable and monogamous relationship for at least 6 months before screening and who plan to maintain this relationship throughout the study period;\n* Participants with erectile dysfunction, in stable and effective treatment with PDE-5 inhibitors;\n* Participants diagnosed with premature ejaculation;\n* Participants with IELT ≤ 2 minutes;\n* Participants with score ≥ 25 points in the erectile function questionnaire;\n* Participants (or partners) who use at least one contraceptive method.\n\nExclusion Criteria:\n\n* Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;\n* Participation in a clinical trial in the year prior to this study;\n* Known hypersensitivity to any of the formula compounds;\n* Participants with cardiovascular disease for whom sexual activity is inadvisable\n* History or current experience of surgical interventions or radiotherapy in the pelvic region, neurological conditions, trauma or infections that are associated with the symptoms premature ejaculation;\n* Diagnosis of other diseases or conditions in the urinary tract;\n* Participants with conditions that may predispose them to priapism;\n* History of severe psychiatric or psychosocial disorders;\n* Participant whose partner has clinically important sexual dysfunctions.",{"count":384,"type":22},232,[363],"The purpose of this study is to evaluate the efficacy and safety of Toronto association in the treatment of both sexual dysfunction: erectile dysfunction and premature ejaculation.",[28,30],[389,30],"Erectile dysfunction","2023-04-11",{"date":392,"type":43},"2023-04-12",{"date":394,"type":22},"2024-07",{"date":396,"type":22},"2026-08",{"name":398,"class":154},"EMS"]